Refractory Lymphomas Active Not Recruiting Phase 2 Trials for Palbociclib (DB09073)

Also known as: Refractory Lymphoma

IndicationStatusPhase
DBCOND0042145 (Refractory Lymphomas)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04439201Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)Treatment